SARS-CoV-2 Delta-variant breakthrough infections in nursing home residents at mid-term after Comirnaty® COVID-19 vaccination.

SARS-CoV-2 Delta variant breakthrough infections in nursing home residents following vaccination with Comirnaty® COVID-19 vaccine were characterized. In total, 201 participants (median age, 87 years; range, 64-100; 133 female) from two nursing homes in the Valencian community (Spain) were included....

Descripción completa

Detalles Bibliográficos
Autores: Torres I, Bellido-Blasco JB, Gimeno C, Burgos JS, Albert E, Moya-Malo R, Gascó-Laborda JC, Tornero A, Soriano J, Meseguer-Ferrer N, Martínez-Serrano M, Ortíz-Rambla J, Buj H, Hernández N, Peiró S, Salas D, Limón R, Vanaclocha H, Sánchez-Payá J, Díez-Domingo J, Comas I, González-Candelas F, Navarro D
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
Repositorio:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
OAI Identifier:oai:isabial.fundanetsuite.com:p8697
Acceso en línea:https://isabial.portalinvestigacion.com/publicaciones8697
Access Level:acceso abierto
Palabra clave:Comirnaty® COVID-19 vaccine
SARS-CoV-2 Delta variant
Spike-reactive T cells.
anti-Spike antibodies
breakthrough infection
nursing home residents
id ES_ae10af4e23bd103afaa9c4bf4fdc5e27
oai_identifier_str oai:isabial.fundanetsuite.com:p8697
network_acronym_str ES
network_name_str España
repository_id_str
spelling SARS-CoV-2 Delta-variant breakthrough infections in nursing home residents at mid-term after Comirnaty® COVID-19 vaccination.Torres IBellido-Blasco JBGimeno CBurgos JSAlbert EMoya-Malo RGascó-Laborda JCTornero ASoriano JMeseguer-Ferrer NMartínez-Serrano MOrtíz-Rambla JBuj HHernández NPeiró SSalas DLimón RVanaclocha HSánchez-Payá JDíez-Domingo JComas IGonzález-Candelas FNavarro DComirnaty® COVID-19 vaccineSARS-CoV-2 Delta variantSpike-reactive T cells.anti-Spike antibodiesbreakthrough infectionnursing home residentsSARS-CoV-2 Delta variant breakthrough infections in nursing home residents following vaccination with Comirnaty® COVID-19 vaccine were characterized. In total, 201 participants (median age, 87 years; range, 64-100; 133 female) from two nursing homes in the Valencian community (Spain) were included. SARS-CoV-2-Spike (S) antibody responses were determined by a lateral flow immunocromatography (LFIC) assay and by quantitative electrochemiluminescent assay in LFIC-negative participants. SARS-CoV-2-S-IFN? T cells were enumerated by flow cytometry in 10 participants. Nasopharyngeal SARS-CoV-2 RNA loads were quantified by RT-PCR assays. Vaccine breakthrough COVID-19 due to the Delta variant occurred in 39 residents (median age, 87 years; range, 69-96; 31 female) at a median of 6.5 months after vaccination (9 requiring hospitalization). Breakthrough infections occurred at a higher rate (P<0.0001) in residents who had not been previously infected with SARS-CoV-2 (naïve) (33/108; 18%) than in those with prior diagnosis of SARS-CoV-2 infection (experienced) (6/93; 6.4%), and were more likely (P<0.0001) to develop in residents who tested negative by LFIC (20/49) at 3 months (3M) after vaccination as compared to their LFIC-positive counterparts (19/142). Among LFIC-negative residents, a trend towards lower plasma anti-RBD antibody levels were noticed in those developing breakthrough infection (P=0.16). SARS-CoV-2 RNA loads in nasopharyngeal specimens were lower in SARS-CoV-2-experienced residents (P<0.001) and in those testing positive by LFIC (P=0.13). Frequency of SARS-CoV-2-S-reactive T cells at 3 months was similar in LFIC-negative residents with (n=7) or without (n=3) breakthrough infection. Prior history of SARS-CoV-2 infection and detection of S-reactive antibodies by LFIC at 3 months are associated with a lower risk of Delta-variant breakthrough infection in nursing home residents at mid-term after Comirnaty® COVID-19 vaccination. This article is protected by copyright. All rights reserved.John Wiley & Sons Inc.2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://isabial.portalinvestigacion.com/publicaciones8697Journal of medical virologyISSN: 10969071ISSNe: 01466615reponame:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicanteinstname:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)Inglésinfo:eu-repo/semantics/openAccessoai:isabial.fundanetsuite.com:p86972026-06-12T10:20:37Z
dc.title.none.fl_str_mv SARS-CoV-2 Delta-variant breakthrough infections in nursing home residents at mid-term after Comirnaty® COVID-19 vaccination.
title SARS-CoV-2 Delta-variant breakthrough infections in nursing home residents at mid-term after Comirnaty® COVID-19 vaccination.
spellingShingle SARS-CoV-2 Delta-variant breakthrough infections in nursing home residents at mid-term after Comirnaty® COVID-19 vaccination.
Torres I
Comirnaty® COVID-19 vaccine
SARS-CoV-2 Delta variant
Spike-reactive T cells.
anti-Spike antibodies
breakthrough infection
nursing home residents
title_short SARS-CoV-2 Delta-variant breakthrough infections in nursing home residents at mid-term after Comirnaty® COVID-19 vaccination.
title_full SARS-CoV-2 Delta-variant breakthrough infections in nursing home residents at mid-term after Comirnaty® COVID-19 vaccination.
title_fullStr SARS-CoV-2 Delta-variant breakthrough infections in nursing home residents at mid-term after Comirnaty® COVID-19 vaccination.
title_full_unstemmed SARS-CoV-2 Delta-variant breakthrough infections in nursing home residents at mid-term after Comirnaty® COVID-19 vaccination.
title_sort SARS-CoV-2 Delta-variant breakthrough infections in nursing home residents at mid-term after Comirnaty® COVID-19 vaccination.
dc.creator.none.fl_str_mv Torres I
Bellido-Blasco JB
Gimeno C
Burgos JS
Albert E
Moya-Malo R
Gascó-Laborda JC
Tornero A
Soriano J
Meseguer-Ferrer N
Martínez-Serrano M
Ortíz-Rambla J
Buj H
Hernández N
Peiró S
Salas D
Limón R
Vanaclocha H
Sánchez-Payá J
Díez-Domingo J
Comas I
González-Candelas F
Navarro D
author Torres I
author_facet Torres I
Bellido-Blasco JB
Gimeno C
Burgos JS
Albert E
Moya-Malo R
Gascó-Laborda JC
Tornero A
Soriano J
Meseguer-Ferrer N
Martínez-Serrano M
Ortíz-Rambla J
Buj H
Hernández N
Peiró S
Salas D
Limón R
Vanaclocha H
Sánchez-Payá J
Díez-Domingo J
Comas I
González-Candelas F
Navarro D
author_role author
author2 Bellido-Blasco JB
Gimeno C
Burgos JS
Albert E
Moya-Malo R
Gascó-Laborda JC
Tornero A
Soriano J
Meseguer-Ferrer N
Martínez-Serrano M
Ortíz-Rambla J
Buj H
Hernández N
Peiró S
Salas D
Limón R
Vanaclocha H
Sánchez-Payá J
Díez-Domingo J
Comas I
González-Candelas F
Navarro D
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Comirnaty® COVID-19 vaccine
SARS-CoV-2 Delta variant
Spike-reactive T cells.
anti-Spike antibodies
breakthrough infection
nursing home residents
topic Comirnaty® COVID-19 vaccine
SARS-CoV-2 Delta variant
Spike-reactive T cells.
anti-Spike antibodies
breakthrough infection
nursing home residents
description SARS-CoV-2 Delta variant breakthrough infections in nursing home residents following vaccination with Comirnaty® COVID-19 vaccine were characterized. In total, 201 participants (median age, 87 years; range, 64-100; 133 female) from two nursing homes in the Valencian community (Spain) were included. SARS-CoV-2-Spike (S) antibody responses were determined by a lateral flow immunocromatography (LFIC) assay and by quantitative electrochemiluminescent assay in LFIC-negative participants. SARS-CoV-2-S-IFN? T cells were enumerated by flow cytometry in 10 participants. Nasopharyngeal SARS-CoV-2 RNA loads were quantified by RT-PCR assays. Vaccine breakthrough COVID-19 due to the Delta variant occurred in 39 residents (median age, 87 years; range, 69-96; 31 female) at a median of 6.5 months after vaccination (9 requiring hospitalization). Breakthrough infections occurred at a higher rate (P<0.0001) in residents who had not been previously infected with SARS-CoV-2 (naïve) (33/108; 18%) than in those with prior diagnosis of SARS-CoV-2 infection (experienced) (6/93; 6.4%), and were more likely (P<0.0001) to develop in residents who tested negative by LFIC (20/49) at 3 months (3M) after vaccination as compared to their LFIC-positive counterparts (19/142). Among LFIC-negative residents, a trend towards lower plasma anti-RBD antibody levels were noticed in those developing breakthrough infection (P=0.16). SARS-CoV-2 RNA loads in nasopharyngeal specimens were lower in SARS-CoV-2-experienced residents (P<0.001) and in those testing positive by LFIC (P=0.13). Frequency of SARS-CoV-2-S-reactive T cells at 3 months was similar in LFIC-negative residents with (n=7) or without (n=3) breakthrough infection. Prior history of SARS-CoV-2 infection and detection of S-reactive antibodies by LFIC at 3 months are associated with a lower risk of Delta-variant breakthrough infection in nursing home residents at mid-term after Comirnaty® COVID-19 vaccination. This article is protected by copyright. All rights reserved.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://isabial.portalinvestigacion.com/publicaciones8697
url https://isabial.portalinvestigacion.com/publicaciones8697
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv John Wiley & Sons Inc.
publisher.none.fl_str_mv John Wiley & Sons Inc.
dc.source.none.fl_str_mv Journal of medical virology
ISSN: 10969071
ISSNe: 01466615
reponame:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
instname_str Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
reponame_str r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
collection r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869416529904271360
score 15,811543

Similares en LA Referencia